Home Blood Testing Devices Market Projected to Reach US$51.2 Billion by 2034 as Glucose Monitoring Dominates
核心洞察
The global home blood testing devices market is projected to grow from US$19.2 billion in 2024 to about US$51.2 billion by 2034, a 10.3% CAGR.
Glucose testing accounted for 49.8% of the 2024 market, driven by roughly 537 million adults worldwide living with diabetes (搜索) in 2021.
North America led with a 42.3% share and US$8.1 billion in 2024 revenue, supported by FDA-cleared devices and telehealth expansion.
The global market for home blood testing devices is forecast to expand from US$19.2 billion in 2024 to approximately US$51.2 billion by 2034, a compound annual growth rate of 10.3% over the 2025–2034 forecast period, according to a new market analysis. The growth reflects a broader shift in healthcare delivery toward decentralized diagnostics, self-monitoring, and personalized disease management, with devices enabling individuals to test at home for glucose, cholesterol, ketones, coagulation parameters, and other biomarkers.
Glucose testing remains the single largest application, accounting for 49.8% of the market in 2024. The segment's dominance is tied directly to the scale of the diabetes (搜索) burden. The International Diabetes Federation (搜索) (IDF) estimated that approximately 537 million adults aged 20–79 years were living with diabetes globally in 2021, a figure projected to rise to 643 million by 2030 and 783 million by 2045. In the United States, the Centers for Disease Control and Prevention (搜索) (CDC) reported that about 38.4 million people had diabetes in 2021, representing roughly 11.6% of the population, while an additional 97.6 million U.S. adults had prediabetes (搜索) — a population requiring regular blood glucose monitoring and preventive management.
Cardiovascular monitoring represents a second major driver. The World Health Organization (WHO) reported that cardiovascular diseases caused approximately 19.8 million deaths globally in 2022, accounting for nearly 32% of all deaths worldwide, increasing demand for home-based testing of cholesterol and other cardiovascular risk indicators.
North America Leads, Asia Pacific Accelerates
North America held the leading regional position in 2024 with a 42.3% share and revenue of US$8.1 billion. The analysis attributes this to high adoption of self-monitoring technologies, advanced healthcare infrastructure, and strong availability of FDA-cleared monitoring devices. The CDC's finding that approximately 1 in 5 U.S. adults with diabetes (搜索) are unaware they have the condition further underscores the role of accessible testing.
Asia Pacific is expected to record significant growth, driven by rising awareness of preventive healthcare, increasing chronic disease prevalence, and improving access to digital health technologies. The IDF reported that the Western Pacific region had approximately 206 million adults living with diabetes (搜索) in 2021. Growing smartphone penetration, healthcare digitization, and expansion of home-based diagnostic services are supporting adoption across Japan, China, and Southeast Asian nations.
Connected Devices and Telehealth Reshape the Category
Technological integration is a central theme in the market's evolution. Modern glucose monitoring devices can deliver results within 5–10 seconds, and connected systems allow healthcare providers to remotely monitor patient conditions and adjust treatment decisions. Manufacturers including Abbott (搜索) and Dexcom (搜索) are developing Bluetooth-enabled devices that link to smartphones for tracking and data sharing, while mobile applications, cloud platforms, and artificial intelligence-based analytics increasingly support personalized health insights.
The expansion of telehealth has reinforced demand for connected home testing. The U.S. Department of Health and Human Services (HHS) reported that Medicare telehealth visits increased from approximately 840,000 in 2019 to 52.7 million in 2020, demonstrating increased acceptance of remote care models that depend on patient-generated diagnostic data. CMS supports remote patient monitoring services for chronic conditions using connected medical devices.
Distribution has also shifted: online stores captured a leading 45.2% share in 2024, ahead of hospital pharmacies, drug stores, and retail stores.
Aging Populations and Preventive Testing Add Momentum
Demographic trends are contributing to demand. According to the U.S. Census Bureau, the number of Americans aged 65 years and older reached 55.8 million in 2020, approximately 16.8% of the U.S. population. Older adults commonly require regular monitoring for chronic diseases, increasing reliance on home diagnostic devices that reduce frequent hospital visits.
The FDA has highlighted that home-use diagnostic tests provide convenience and allow individuals to track health conditions without frequent clinical visits, supporting a broader shift toward preventive healthcare testing and early detection.
The analysis projects continued expansion as connected diagnostics, wearable monitoring technologies, and personalized healthcare solutions gain adoption, with rising chronic disease prevalence and demand for convenient care expected to sustain innovation in home-based testing.